Yvonne Nong, Justin W Marson, Kristina Derrick, Edward Heilman, Jane Schneider, Jessica L Feig, Daniel M Siegel
{"title":"An Unusual Case of Psoriasiform Dermatitis Treated With Dual Biologic Therapy and Literature Review.","authors":"Yvonne Nong, Justin W Marson, Kristina Derrick, Edward Heilman, Jane Schneider, Jessica L Feig, Daniel M Siegel","doi":"10.36849/JDD.8382","DOIUrl":null,"url":null,"abstract":"<p><p>Previously believed to be of distinct immunopathogenesis, atopic dermatitis (AD) and psoriasis (PsO) spectrum may permit immunologic shifts to favor the opposing inflammatory states following biologic treatment. Cases of AD that developed following PsO biologics are increasingly reported in the literature. While biologic monotherapy is becoming more widely available, dual biologic therapies have been understudied. Here, we present a patient with biopsy-confirmed PsO who developed psoriasiform spongiotic dermatitis following anti-IL-17A initiation who responded to combination anti-IL-23 and anti-IL-4Ra therapy and discussed the PsO-AD immunologic spectrum and use of dual biologic therapies. J Drugs Dermatol. 2025;24(2):207-211. doi:10.36849/JDD.8382R1.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"207-211"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8382","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Previously believed to be of distinct immunopathogenesis, atopic dermatitis (AD) and psoriasis (PsO) spectrum may permit immunologic shifts to favor the opposing inflammatory states following biologic treatment. Cases of AD that developed following PsO biologics are increasingly reported in the literature. While biologic monotherapy is becoming more widely available, dual biologic therapies have been understudied. Here, we present a patient with biopsy-confirmed PsO who developed psoriasiform spongiotic dermatitis following anti-IL-17A initiation who responded to combination anti-IL-23 and anti-IL-4Ra therapy and discussed the PsO-AD immunologic spectrum and use of dual biologic therapies. J Drugs Dermatol. 2025;24(2):207-211. doi:10.36849/JDD.8382R1.
期刊介绍：
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
